{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-027326","form_type":"8-K","ticker":"IDXX","cik":"0000874716","company_name":"IDEXX LABORATORIES INC /DE","filed_at":"2022-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.383824+00:00","generated_at":"2026-06-24T06:12:16.971694+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"IDEXX Q2 revenue $861M +4% reported; EPS $1.56 -33%; cuts FY2022 guidance","bullets":["Revenue $861M, up 4% reported and 6.5% organic; CAG Diagnostics recurring revenue +4% reported, +7% organic.","EPS $1.56, down 33% as reported, including $0.72 impact from $80M discrete R&D investments.","Record Q2 premium instrument placements up 18% YoY; global installed base +15%.","Updated FY2022 revenue guidance $3,305-$3,385M (3%-5.5% reported, 5.5%-8% organic); EPS $7.77-$8.05.","U.S. same-store clinical visits declined 3% in Q2 vs +13% prior year; diagnostics revenue +6% same-store."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-027326","json":"https://secwatch.observer/filing/0001564590-22-027326.json","markdown":"https://secwatch.observer/filing/0001564590-22-027326.md","text":"https://secwatch.observer/filing/0001564590-22-027326.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874716/000156459022027326/0001564590-22-027326-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874716/000156459022027326/idxx-8k_20220802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T06:12:16.971694+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}